Compare HKPD & BFRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HKPD | BFRG |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 10.7M |
| IPO Year | 2024 | 2022 |
| Metric | HKPD | BFRG |
|---|---|---|
| Price | $0.40 | $0.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 111.1K | ★ 127.6K |
| Earning Date | 08-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $116,670.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 79.49 |
| 52 Week Low | $0.31 | $0.43 |
| 52 Week High | $2.58 | $2.04 |
| Indicator | HKPD | BFRG |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 43.95 |
| Support Level | $0.38 | $0.51 |
| Resistance Level | $0.45 | $0.69 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 27.18 | 25.67 |
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. The Company is focused specifically on advance artificial intelligence and machine learning (AI/ML)- driven analysis of complex datasets in medicine and healthcare. The Company's objective is to use its AI/ML platform to provide a precision-medicine approach to drug-asset enablement through external partnerships and selective internal development.